SLCO1B1
HGNC ↗3 article(s) in the watch · Pharmacogenomics
SLCO1B1 encodes the hepatic organic-anion transporter OATP1B1, involved in statin uptake. The c.521T>C (*5) variant increases the risk of statin-associated myopathy, particularly with simvastatin (CPIC guidelines).
Drugs involved: statins (notably simvastatin) — myopathy risk
Recommendation: CPIC level A
Curated publications
Biomarker-Based Prediction of OATP1B1 Activity in Clinical Routine — Investigating Coproporphyrins as Markers for Drug-Drug-Gene Interactions.
SLCO1B1 phenoconversion in clinical routine: detection by endogenous biomarker
Using physiologically based pharmacokinetic modelling to optimize repaglinide and irbesartan dosing in Chinese population with SLCO1B1 polymorphism.
Type 2 diabetes and hypertension - repaglinide-irbesartan interaction
Genetic variation in SLCO1B1 is associated with methotrexate intolerance symptoms in juvenile idiopathic arthritis patients
Juvenile idiopathic arthritis — methotrexate intolerance
Frequently asked questions
Which drugs are affected by SLCO1B1 in pharmacogenomics?+
statins (notably simvastatin) — myopathy risk — CPIC level A
How many Geno'X publications cover the SLCO1B1 gene?+
3 publication(s) on SLCO1B1 have been selected, summarised and scored by Geno'X on a public grading grid (domains: Pharmacogenomics).